|
|
||||||||
Clinical Studies |
Departments of Woman and Child Health and Diagnostic Radiology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
AIM: To study bone mass, body composition and androgenic/anabolic activity in adult women with virilizing congenital adrenal hyperplasia (CAH) treated with glucocorticoids since infancy and to relate this to the postmenarcheal glucocorticoid impact. PATIENTS AND METHODS: Thirteen adult women with virilizing CAH treated with gluco- and mineralocorticoids but otherwise medicine-free were investigated with respect to bone mineral content, body composition by dual energy X-ray absorptiometry and endocrine status. In addition an index of accumulated postmenarcheal exogenous glucocorticoid impact was calculated. Seven of the patients had regular menstrual periods, and six were oligomenorrheic but responded with withdrawal bleedings on cyclic progestagens. The data for the patients were compared with those of age-matched healthy reference subjects. RESULTS: In spite of their shorter stature, CAH patients were significantly heavier and had a significantly higher body mass index and fat/lean body mass ratio than the controls. Their bone mineral area density (BMD) was significantly lower than that of the controls. Serum concentrations of androgens were subnormal in all except two of the patients. Strong negative associations were found between BMD and the calculated index of accumulated postmenarcheal glucocorticoid dose but not between BMD and circulating androgen levels. CONCLUSION: The results indicate that glucocorticoids were administered in excess in most of the patients, resulting in subnormal levels of adrenocortical androgens, increased body fat and bone demineralization. Increased catabolic activity due to hypercortisolism rather than decreased androgenic/anabolic steroids is probably the major cause of the subnormal BMD in the treated CAH patients.
This article has been cited by other articles:
![]() |
Z. Chakhtoura, A. Bachelot, D. Samara-Boustani, J.-C. Ruiz, B. Donadille, J. Dulon, S. Christin-Maitre, C. Bouvattier, M.-C. Raux-Demay, P. Bouchard, et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur. J. Endocrinol., June 1, 2008; 158(6): 879 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Falhammar, H. Filipsson, G. Holmdahl, P.-O. Janson, A. Nordenskjold, K. Hagenfeldt, and M. Thoren Fractures and Bone Mineral Density in Adult Women with 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4643 - 4649. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Burt, G. Johannsson, A. M. Umpleby, D. J. Chisholm, and K. K. Y. Ho Impact of Acute and Chronic Low-Dose Glucocorticoids on Protein Metabolism J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3923 - 3929. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Falhammar, H. Filipsson, G. Holmdahl, P.-O. Janson, A. Nordenskjold, K. Hagenfeldt, and M. Thoren Metabolic Profile and Body Composition in Adult Women with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 110 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sciannamblo, G. Russo, D. Cuccato, G. Chiumello, and S. Mora Reduced Bone Mineral Density and Increased Bone Metabolism Rate in Young Adult Patients with 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4453 - 4458. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. King, A. B. Wisniewski, B. J. Bankowski, K. A. Carson, H. A. Zacur, and C. J. Migeon Long-Term Corticosteroid Replacement and Bone Mineral Density in Adult Women with Classical Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 865 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. M. L. Stikkelbroeck, W. J. G. Oyen, G.-J. van der Wilt, A. R. M. M. Hermus, and B. J. Otten Normal Bone Mineral Density and Lean Body Mass, but Increased Fat Mass, in Young Adult Patients with Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1036 - 1042. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |